IMPAX LABORATORIES INC's ticker is IPXL and the CUSIP is 45256B101. A total of 165 filers reported holding IMPAX LABORATORIES INC in Q4 2013. The put-call ratio across all filers is 0.63 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $843,000 | -55.3% | 50,604 | -45.5% | 0.01% | -52.9% |
| Q3 2017 | $1,885,000 | +229.5% | 92,880 | +161.2% | 0.02% | +240.0% |
| Q2 2017 | $572,000 | -35.7% | 35,554 | -5.2% | 0.01% | -44.4% |
| Q3 2016 | $889,000 | -89.8% | 37,512 | -86.2% | 0.01% | -85.7% |
| Q1 2016 | $8,711,000 | -9.4% | 272,037 | +21.0% | 0.06% | -7.4% |
| Q4 2015 | $9,617,000 | +28.4% | 224,901 | +5.7% | 0.07% | +51.1% |
| Q3 2015 | $7,490,000 | +515.4% | 212,733 | +702.7% | 0.04% | +462.5% |
| Q2 2015 | $1,217,000 | +905.8% | 26,502 | +924.8% | 0.01% | +700.0% |
| Q1 2015 | $121,000 | -87.1% | 2,586 | -91.2% | 0.00% | -80.0% |
| Q4 2014 | $936,000 | +800.0% | 29,535 | +574.0% | 0.01% | +400.0% |
| Q3 2014 | $104,000 | -33.8% | 4,382 | -29.8% | 0.00% | 0.0% |
| Q4 2013 | $157,000 | -66.3% | 6,240 | -72.5% | 0.00% | -50.0% |
| Q3 2013 | $466,000 | – | 22,726 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 5,415,600 | $162,414,000 | 1.91% |
| Broadfin Capital, LLC | 1,217,858 | $36,524,000 | 1.80% |
| NEW AMSTERDAM PARTNERS LLC/NY | 695,100 | $20,846,000 | 1.36% |
| Healthcare Value Capital, LLC | 50,000 | $1,500,000 | 1.26% |
| Iguana Healthcare Management, LLC | 75,000 | $2,249,000 | 1.05% |
| Matarin Capital Management, LLC | 78,292 | $2,347,977,000 | 1.04% |
| Independence Capital Asset Partners, LLC | 253,089 | $7,590,000 | 1.04% |
| Tekla Capital Management LLC | 344,683 | $10,337,000 | 0.95% |
| Penn Capital Management Company, LLC | 794,641 | $23,831,000 | 0.92% |
| Leonard Capital Management, Inc. | 87,661 | $2,629,000 | 0.89% |